These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3861893)

  • 41. [Differentiation induction of myeloid leukemia cells by glucocorticoid--the differentiation induction effect in vitro and in vivo].
    Nakamaki T; Sakashita A; Sano M; Hino K; Suzuki K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1989 Feb; 30(2):149-57. PubMed ID: 2746870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Study of the antileukemic effect of thiosulfonic acid esters].
    Zaretskiĭ II; Khomchenovskiĭ EI; Smirnova GS
    Patol Fiziol Eksp Ter; 1966; 10(5):72-3. PubMed ID: 5240294
    [No Abstract]   [Full Text] [Related]  

  • 43. Current understanding of the application of pyridinium oximes as cholinesterase reactivators in treatment of organophosphate poisoning.
    Jokanović M; Stojiljković MP
    Eur J Pharmacol; 2006 Dec; 553(1-3):10-7. PubMed ID: 17109842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of differentiation of Rauscher virus-induced mouse myeloid leukemia cells with a factor(s) in ascitic fluid and inhibitors of nucleic acid and protein syntheses.
    Sugiyama K; Hozumi M; Okabe J
    Cancer Res; 1979 Mar; 39(3):1056-62. PubMed ID: 427746
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib.
    Védy D; Muehlematter D; Rausch T; Stalder M; Jotterand M; Spertini O
    J Clin Oncol; 2010 Jan; 28(3):e33-5. PubMed ID: 19901109
    [No Abstract]   [Full Text] [Related]  

  • 46. Biological properties of dipyridyl sulphides and related compounds.
    Boduszek B; Wieczorek JS; Mordarski M; Wieczorek J
    Arch Immunol Ther Exp (Warsz); 1985; 33(2):331-8. PubMed ID: 4084010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Recent advances in the understanding and management of acute myeloid leukemia].
    Lishner M; Buskila D; Ravid M
    Harefuah; 1990 Dec; 119(11):375-8. PubMed ID: 2289717
    [No Abstract]   [Full Text] [Related]  

  • 48. Up-regulation of NKG2D ligands by AML cells to increase sensitivity to NK cells: the tumour might strike back. Comment on "differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis" by Rohner et al. [Leuk Res 2007;31:1393-402].
    Zimmer J; Michel T; Andrès E; Hentges F
    Leuk Res; 2008 Apr; 32(4):676-7. PubMed ID: 17920678
    [No Abstract]   [Full Text] [Related]  

  • 49. Culture studies in vitro in human leukemia.
    Spitzer G; Verma DS; Dicke KA; McCredie KB
    Semin Hematol; 1978 Oct; 15(4):352-78. PubMed ID: 366760
    [No Abstract]   [Full Text] [Related]  

  • 50. Prolongation of survival time of mice inoculated with myeloid leukemia cells by inducers of normal differentiation.
    Honma Y; Kasukabe T; Okabe J; Hozumi M
    Cancer Res; 1979 Aug; 39(8):3167-71. PubMed ID: 287553
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The treatment of acute myeloid leukemia].
    Benvenisty DS
    Harefuah; 1972 Jan; 82(2):96-7. PubMed ID: 4508194
    [No Abstract]   [Full Text] [Related]  

  • 52. Membrane-permeant, bioactivatable analogues of cGMP as inducers of cell death in IPC-81 leukemia cells.
    Schwede F; Brustugun OT; Zorn-Kruppa M; Døskeland SO; Jastorff B
    Bioorg Med Chem Lett; 2000 Mar; 10(6):571-3. PubMed ID: 10741556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antileukemic effect of alkyl phospholipids. II. Prolongation of survival times of leukemic mice by alkyl ethyleneglycophospholipids.
    Honma Y; Kasukabe T; Okabe-Kado J; Hozumi M; Tsushima S; Nomura H
    Cancer Chemother Pharmacol; 1983; 11(2):77-9. PubMed ID: 6578883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The in vivo antitumor activity of cardiac glycosides in mice xenografted with human cancer cells is probably an experimental artifact.
    Calderón-Montaño JM; Burgos-Morón E; López-Lázaro M
    Oncogene; 2014 May; 33(22):2947-8. PubMed ID: 23752179
    [No Abstract]   [Full Text] [Related]  

  • 55. Alkyl-lysophospholipids inhibit the growth of hypernephroid carcinomas in vitro.
    Berdel WE; Fink U; Egger B; Reichert A; Munder PG; Rastetter J
    J Cancer Res Clin Oncol; 1981; 101(3):325-30. PubMed ID: 7309782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heterocyclic alkylphospholipids with an improved therapeutic range.
    Hilgard P; Stekar J; Klenner T; Nössner B; Kutscher B; Engel J
    Adv Exp Med Biol; 1996; 416():157-64. PubMed ID: 9131142
    [No Abstract]   [Full Text] [Related]  

  • 57. [Structural changes of cell membrane and cell differentiation induction].
    Honma Y
    Nihon Rinsho; 1985 Apr; 43(4):706-8. PubMed ID: 3861893
    [No Abstract]   [Full Text] [Related]  

  • 58. Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophospholipids.
    Honma Y; Kasukabe T; Hozumi M; Tsushima S; Nomura H
    Cancer Res; 1981 Aug; 41(8):3211-6. PubMed ID: 6941852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Experimental models for the treatment of acute myeloid leukemia].
    Burchenal JH
    Recenti Prog Med; 1975 Sep; 59(3):222-31. PubMed ID: 772768
    [No Abstract]   [Full Text] [Related]  

  • 60. Differentiation induction therapy of acute myelogenous leukaemias.
    Hassan HT
    Haematologia (Budap); 1988; 21(3):141-50. PubMed ID: 3053358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.